SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs

Somatostatin Receptor Antagonist PET/CT for Pre-operative N Stage Evaluation in Patients With Gastro-entero-pancreatic Neuroendocrine Tumors

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06344832

Enrollment

Registered

2024-04-03

Start date

2024-04-01

Completion date

2030-03-01

Last updated

2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro-entero-pancreatic Neuroendocrine Tumor

Brief summary

The research aims to prospectively include patients with GEP-NENs, undergo preoperative imaging assessment (including PET/CT and contrast-enhanced CT), and accurately delineate lymph node regions. Through postoperative pathological reports, the diagnostic performance of lymph node metastasis (LNM) in GEP-NENs is evaluated. Factors influencing the diagnostic accuracy of SSTR-PET/CT and contrast-enhanced CT are also investigated.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age \> 18 years old; 2. Patients diagnosed with GEP-NEN by surgical pathology; 3. Complete medical records including basic information and treatment process; 4. Patients who have undergone preoperative contrast-enhanced CT and 68Ga-SSTR-PET/CT, and have consented to the 68Ga-SSTR-PET/CT project in the Nuclear Medicine Department.

Exclusion criteria

1. Presence of concomitant malignancies; 2. Cases diagnosed pathologically as non-GEP-NEN.

Design outcomes

Primary

Measure	Time frame	Description
lymph node metastasis status	2024.04.01~2030.03.01	lymph node metastasis status confirmed by histopathology

Outcome results